Sunday, November 1, 2026

USD/EUR Over 2% Up In The Last 10 Sessions

USD/EUR Over 2% Up In The Last 10 Sessions

(VIANEWS) - USD/EUR (USDEUR) has been up by 2.18% for the last 10 sessions. At 23:09 EST on Thursday, 27 July, USD/EUR (USDEUR) is $0.91.

USD/EUR's yearly highs and lows, it's 2.616% up from its 52-week low and 13.175% down from its 52-week high.

Forex Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, USD/EUR's Forex is considered to be oversold (<=20).

News about

  • Usd/jpy to quickly target 145 on a dovish boj outcome – credit suisse. According to FXStreet on Wednesday, 26 July, "We stick tight to our USD/JPY 135-152 forecast range for the quarter and would expect spot to target 145 quickly if the BoJ meets our expectations, especially if the Fed's hike this week is not interpreted as a dovish one."
  • Usd/jpy can push back to the recent high at 145 on no change in the boj's YCC policy – ING. According to FXStreet on Thursday, 27 July, "If the BoJ decides to leave the current policy settings unchanged, then USD/JPY looks as though it can push back to the recent high at 145.", "If the BoJ surprises the market with a YCC tweak as we forecast, or gives a hint of possible policy adjustment in the near future, then USD/JPY could break lower - perhaps even lower than the recent low of 137 as the market would be taken by surprise. "
  • Usd/jpy technical analysis: US central bank policies will determine the fate - 26 July 2023. According to DailyForex on Wednesday, 26 July, "According to the performance on the daily chart below, and despite the recent selling, the general trend of the USD/JPY currency pair is still bullish and will remain so as long as it is stable above the psychological resistance at 140.00. ", "It must be taken into account that the USD/JPY pair has another important date on Friday when the Japanese central bank will announce its monetary policy update."
  • Usd/jpy price analysis: bounces off 140.90 key support as US dollar, yields rebound on fed, boj concerns. According to FXStreet on Wednesday, 26 July, "In a case where the USD/JPY pair remains firmer past 142.00, the odds of witnessing a run-up towards 144.00 and then to the yearly high marked in June around 145.00 can't be ruled out.", "Looking forward, the USD/JPY is likely to extend the latest run-up towards the 21-DMA hurdle of around 141.60 before challenging the previous weekly high of near the 142.00 threshold."
  • Usd/jpy price analysis: breaks nearby support to slip beneath 140.00 as yen traders await US gdp, boj. According to FXStreet on Thursday, 27 July, "Amid these plays, the USD/JPY pair is likely to extend the latest fall towards the 50% Fibonacci retracement of its May-June upside, near 139.30.", "Even so, the 200-SMA level of around 141.65 at the latest will act as the final defense of the USD/JPY bears."

More news about USD/EUR (USDEUR).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Catalyst Cluster: Ivonescimab's PDUFA Date and Small-Cap Biotech Delistings
ESMO 2026 (Oct 22-24) concentrates a wave of oncology readouts. Summit's ivonescimab (10 presentations, positive HARMONi-GI1 OS, new EA2251 Phase II/III with ECOG-ACRIN) leads, ahead of its FDA PDUFA date of 2026-11-14, and Daiichi Sankyo's DXd ADC platform (REJOICE-Ovarian, DESTINY-Lung04, TUXEDO-3) follows. At the other end of the capital-markets spectrum, micro-cap Spago Nanomedical is moving to delist from Nasdaq First North (board resolution Oct 22, EGM Nov 19, application Jan 2027). Pivotal data and regulatory milestones are rewarding well-funded late-stage players, while cash-constrained early-stage developers are exiting public markets.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,525 source documents archived
Query this data → isubstrate.com